Navigation Links
Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
Date:4/15/2013

FREMONT, Calif., April 15, 2013 /PRNewswire/ -- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today the appointment of Kleanthis G. Xanthopoulos , Ph.D., to its Board of Directors. Dr. Xanthopoulos is President & Chief Executive Officer of Regulus Therapeutics Inc. (NASDAQ: RGLS), a leading company developing microRNA therapeutics.

"I am pleased to welcome Dr. Xanthopoulos as our independent board member," said Vikram Lamba, Chief Executive Officer of Zosano Pharma. "He is a veteran life sciences industry CEO whose extensive healthcare, execution and IPO experience will provide Zosano with valuable insight as we pursue potential public options for financing our extensive clinical development program."

Prior to joining Regulus in 2007, Dr. Xanthopoulos was a managing director of Enterprise Partners Venture Capital. He co-founded and served as President and Chief Executive Officer of Anadys Pharmaceuticals, and remained a Director until its acquisition by Roche. He was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals), and participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute. Previously, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden after completing a Postdoctoral Research Fellowship at The Rockefeller University, New York. An Onassis Foundation scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received
'/>"/>

SOURCE Zosano Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Zosano Pharma, Inc. Announces Key Strategic Hire
2. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
3. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
4. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
5. InnoPharma, Inc., Announces U.S. FDA Approval of Acetylcysteine Solution, USP, 20% for Inhalation or Oral Administration
6. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
7. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
8. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
9. DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
10. As Smartphone Usage Expands, Survey Says Nurses and Nursing Students Want Mobile Access to Credible Drug Data
11. BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  AliveCor, Inc. ... Drug Administration (FDA) has granted the company ... fibrillation (AFib), the most common form of ... instantly detects if patients are experiencing AFib ... the mobile phone based AliveCor® Heart Monitor, ...
(Date:8/21/2014)... , Aug. 21, 2014   Royal Philips ... today announced it has received 510(k) clearance from ... its precision planning application for Transcatheter Aortic-Valve Implantation ... application provides interventionalists with pre-procedural, high-precision positioning to ... TAVI planning application is available as part of ...
(Date:8/20/2014)... 20, 2014 Northstar Global Business Services, ... months of hard work from many talented specialists, ... formulation and package design.  The new formulation for ... into the product due to overwhelming evidence of ... Snorenz Nighttime will also include these vitamins, as ...
Breaking Medicine Technology:AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Northstar completes the first phase of its new retail strategy and prepares to ship reformulated Snorenz with all new packaging 2
... Reported in 4Q 2007 -, LA JOLLA, ... TPTX ) today announced that it has completed,enrollment ... for the treatment,of acute migraine headache. Tezampanel is ... non-vascular and non-serotonergic,approach to the management of pain ...
... 3 trial of Genasense(R) seeks to confirm benefit in melanoma -- ... Company regains compliance for NASDAQ Global Markets listing; Genta common stock ... program for Genasense will continue ... during Phase 3 trial ...
Cached Medicine Technology:TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache 2TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache 3TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache 4Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 2Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 3Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 4Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 5Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 6Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 7Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 8
(Date:8/21/2014)... chronic kidney disease patients may be a strong indicator ... in the Journal of the American Society of ... Hopkins Bloomberg School of Public Health assert that coronary ... atherosclerosis in predicting the risk of heart disease among ... all patients with chronic kidney disease (CKD) die from ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pulmonary ... with an Education Forum for PH patients and ... Who:    The Pulmonary Hypertension Association – the ... find ways to prevent and cure pulmonary hypertension ... affects the functioning of the heart and can ...
(Date:8/21/2014)... Researchers have pinpointed the environmental source of fungal infections ... for decades. It literally grows on trees. , The ... 13-year-old girl, who spent the summer gathering soil and ... by infections of the fungus named Cryptococcus gattii ... which encompasses a number of species including C. ...
(Date:8/21/2014)... -- Black mothers are less likely than white moms ... why: Hospitals in neighborhoods with many black residents do ... more white residents, a U.S. government study finds. ... in medical centers where the black population is higher ... Control and Prevention reported Thursday. These practices include ...
(Date:8/21/2014)... THURSDAY, Aug. 21, 2014 (HealthDay News) -- Among seniors, ... suggests. The study involved more than 2,500 people, aged ... the study and again two, six and eight years later. ... in the person,s risk of death during the study period, ... and effect, researchers led by Sharon Christ of Purdue University ...
Breaking Medicine News(10 mins):Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 3Health News:Fungus deadly to AIDS patients found to grow on trees 2Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2
... Interim Results from National Chronic Disease ... ... participants in the Diabetes Ten City Challenge (DTCC) improved across,all ... of,the program, the American Pharmacists Association (APhA) Foundation,announced today., ...
... CHAPEL HILL, N.C., March 12 R&D structure ... is,essential to pharmaceutical companies. In a competitive market ... process increases -- the need to have an,optimized ... Discover the best-suited organizational structure that promotes rapid,growth, ...
... Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) ... Annual Lehman Brothers Global Healthcare Conference will ... visiting the Investors section of the,Company,s website, ... ), The presentation will include ...
... XTNT ) today announced that Gregory D. Casciaro, ... Company,s 28th Annual,Health Care Conference on Tuesday, March 18, ... at the Boston Marriot Copley Place in Boston, MA., ... device company focused on developing and,commercializing innovative customizable drug ...
... its ongoing effort to,give consumers information to improve ... four area hospitals have been,selected as Blue Distinction ... Distinction(R) is a nationwide program created to give ... and to work with their,health care providers to ...
... 12 Accuray,Incorporated (Nasdaq: ARAY ), a global ... company received the 2008 North American Medical,Devices Product of ... Sullivan, for its CyberKnife(R) Robotic Radiosurgery System., The ... is presented each,year to the company that has demonstrated ...
Cached Medicine News:Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 2Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 3Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 4Health News:R&D Quality Excellence: Proven Tactics Optimize the R&D Quality Organizations of Pharmaceutical and Biotech Industries 2Health News:Eleventh Annual Lehman Brothers Global Healthcare Conference to Webcast Millennium Presentation 2Health News:Independence Blue Cross Announces Blue Distinction Centers for Complex and Rare Cancers(SM) in Philadelphia 2Health News:Independence Blue Cross Announces Blue Distinction Centers for Complex and Rare Cancers(SM) in Philadelphia 3Health News:Accuray's CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan 2Health News:Accuray's CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan 3
... Line ULTRA® Suctionaid® tracheostomy tubes provide an ... secretions from above the tracheostomy tube cuff. ... tracheostomy tubes provide an additional lumen to ... the tracheostomy tube cuff helping to reduce ...
Fenestrations allow your patients to vocalize when cuff is deflated...
The all silicone construction of the shaft and neck flange provides the utmost in patient comfort. , ,The Aire-Cuf® tracheostomy tube offers a more traditional and familiar air-filled cuff desig...
... Built-in 15 mm ISO termination for ... inner cannula in place. , ,Clearly ... inner cannula system , ,The Portex® ... constructed of siliconized polyvinyl chloride, providing a ...
Medicine Products: